This CLIA-waived test uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and B viral nucleoprotein antigens in nasal and nasopharyngeal swab and nasopharyngeal aspirate/wash specimens taken directly from symptomatic patients.